



ASX and Media Release

Viralytics to Present CAVATAK™ Clinical Data at Upcoming Conferences

21 September 2016, Sydney, Australia: Viralytics Limited (ASX: VLA, OTCQX: VRACY) today announced that updates on the CAVATAK clinical program will be presented at the [10th International Meeting on Replicating Oncolytic Virus Therapeutics](#) and the [European Society for Medical Oncology 2016 Congress](#) in October.

The poster and podium presentations will provide updated information on the completed Phase 2 CALM and Phase 1/2 CANON trials and the ongoing Phase 1b KEYNOTE 200 / STORM, Phase 1b MITCI and Phase 1b CAPRA trials of Viralytics' lead drug candidate, CAVATAK™ in advanced melanoma, lung cancer and bladder cancer patients. CAVATAK is a novel cancer immunotherapy based on a proprietary cold virus that has been shown to preferentially infect and attack cancer cells.

10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, October 1 – 5 2016.

Monday, October 3

CALM Extension Trial

Podium Presentation

- ***Phase II CALM Extension study: Intratumoural Coxsackievirus A21 increases immune-cell infiltrates and up-regulates immune-checkpoint molecules in the tumour micro-environment***
- Dr Darren Shafren (Chief Scientific Officer, Viralytics)
- Monday, October 3 (7pm Pacific time, 1pm Sydney time October 4)

Tuesday, October 4

CANON Trial

Podium Presentation

- ***Phase I/II CANON study: Oncolytic immunotherapy for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) using Intravesical Coxsackievirus A21***
- Professor Hardev Pandha (Professor of Medical Oncology, University of Surrey)
- Tuesday, October 4 (2pm Pacific time, 8am Sydney time on October 5)



Both presentations will be available from the Viralytics website prior to 10am Sydney time on the day of presentation.

European Society for Medical Oncology, Copenhagen, October 7 – 11 2016

Sunday October 9

CAPRA Trial

Poster Presentation

- ***Phase Ib study of intratumoral oncolytic coxsackievirus A21 (CVA21) and pembrolizumab in subjects with advanced melanoma***
(Abstract 1157TiP¹)
- Poster Session: Immunotherapy of Cancer
- Sunday, October 9, 2016, 1PM – 2PM Central European Time (10-11PM Sydney time on October 9)
- Location: Hall E

KEYNOTE 200 / STORM Trial

Poster Presentation

- ***Intravenous coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients: Phase Ib KEYNOTE 200 study***
(Abstract 1104TiP¹)
- Poster Session: Immunotherapy of Cancer
- Sunday, October 9, 2016, 1PM – 2PM Central European Time (10-11PM Sydney time on October 9)
- Location: Hall E

¹ To comply with the admission criteria for the ESMO Conference, Trials in Progress posters can only include information on Background and Trial Design. Any abstracts which include results or preliminary data will not be accepted by the Conference Scientific Committee.



Monday October 10

MITCI Trial

Poster Discussion Presentation

- ***The MITCI (phase 1b) study: A novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma***
(Abstract 1051PD)
- Monday, October 10, 2016, 9.30AM – 10.30AM Central European Time (6.30PM - 7.30PM Sydney time on October 10)
- Location: Berlin Room

CANON Trial

Poster Discussion Presentation

- ***Phase I/II CANON study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21***
(Abstract 1054PD)
- Monday, October 10, 2016, 9.30AM – 10.30AM Central European Time (6.30PM - 7.30PM Sydney time on October 10)
- Location: Berlin Room

The abstracts will be available on the European Society for Medical Oncology Meeting website at 12 noon Central European time on September 28 (8pm Sydney time on September 28). They will also be available on the Viralytics website at this time.

<http://www.esmo.org/Conferences/ESMO-2016-Congress>

The full posters can be located from the Viralytics website on the date of the presentation.

<http://www.viralytics.com/our-pipeline/scientific-presentations/scientific-presentations-2016/>

About Viralytics Ltd:

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. The company's lead investigational product, CAVATAK™, is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as bladder and lung cancers. CAVATAK is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins



highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit www.viralytics.com.

Enquiries:

Dr Malcolm McColl
Chief Executive Officer
02 9988 4000

Mr Rudi Michelson
Monsoon Communications
03 9620 3333